Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

PURPOSE: Colony-stimulating factor-3 receptor (CSF3R)-T618I is a recurrent activating mutation in chronic neutrophilic leukemia (CNL) and to a lesser extent in atypical chronic myeloid leukemia (aCML) resulting in constitutive JAK-STAT signaling. We sought to evaluate safety and efficacy of the JAK1...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Dao, Kim-Hien T., Gotlib, Jason, Deininger, Michael M.N., Oh, Stephen T., Cortes, Jorge E., Collins, Robert H., Winton, Elliot F., Parker, Dana R., Lee, Hyunjung, Reister, Anna, Schultz, Savage, Samantha, Stevens, Brockett, Chase, Subbiah, Nan, Press, Richard D., Raess, Philipp W., Cascio, Michael, Dunlap, Jennifer, Chen, Yiyi, Degnin, Catherine, Maxson, Julia E., Tognon, Cristina E., Macey, Tara, Druker, Brian J., Tyner, Jeffrey W.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2020
Assuntos:
RAPID COMMUNICATIONS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7106977/
https://ncbi.nlm.nih.gov/pubmed/31880950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00895
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares